237 666

Cited 8 times in

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)

DC Field Value Language
dc.contributor.author김범경-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author윤기태-
dc.contributor.author이정일-
dc.contributor.author한광협-
dc.date.accessioned2017-10-26T08:13:12Z-
dc.date.available2017-10-26T08:13:12Z-
dc.date.issued2016-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/153153-
dc.description.abstractBACKGROUND/AIMS: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB). METHODS: In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) or to continue their current therapy (ADV+NA group, n=16). The primary end point was the proportion of patients with complete virological response (CVR, defined as serum HBV DNA <60 IU/mL) at 48 weeks. RESULTS: The median age was 52 years (16 men), and 28 were positive for hepatitis B e antigen (HBeAg). The baseline characteristics did not differ significantly between the two groups. The proportion with CVR was significantly higher in the TDF+NA group than in the ADV+NA group at 24 weeks (81.3% vs. 25.0%, P=0.001) and 48 weeks (87.5% vs. 37.5%, P=0.002). Furthermore, a decrease in the serum HBV DNA level of >2log10 IU/mL was more likely in the TDF+NA group at both 24 and 48 weeks (68.8% vs. 56.3%, P=0.014 vs. 81.3% vs. 56.3%, P=0.001, respectively). During the follow-up, the rate of HBeAg seroconversion was higher in the TDF+NA group than the ADV+NA group (12.5% vs. 6.25%, P=0.640), as was that for the hepatitis B surface antigen (6.25% vs. 0%, P=0.080). No serious adverse events due to antiviral agents occurred. CONCLUSION: In patients exhibiting suboptimal responses to ADV+NA therapy for NA-resistant CHB, switching from ADV to TDF might provide better virological outcomes.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenine/analogs & derivatives*-
dc.subject.MESHAdenine/therapeutic use-
dc.subject.MESHAlanine Transaminase/blood-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHDNA, Viral/blood-
dc.subject.MESHDrug Resistance, Viral-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHGenotype-
dc.subject.MESHHepatitis B e Antigens/blood-
dc.subject.MESHHepatitis B virus/genetics-
dc.subject.MESHHepatitis B, Chronic/drug therapy*-
dc.subject.MESHHumans-
dc.subject.MESHLamivudine/therapeutic use-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOrganophosphonates/therapeutic use*-
dc.subject.MESHProspective Studies-
dc.subject.MESHTenofovir/therapeutic use*-
dc.subject.MESHTreatment Outcome-
dc.titleEfficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)-
dc.typeArticle-
dc.publisher.locationKorea-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorMoon Young Kim-
dc.contributor.googleauthorJung Il Lee-
dc.contributor.googleauthorYoung Suk Kim-
dc.contributor.googleauthorKi Tae Yoon-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorSang Hoon Ahn-
dc.identifier.doi10.3350/cmh.2016.0037-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA02544-
dc.contributor.localIdA03122-
dc.contributor.localIdA04268-
dc.contributor.localIdA00487-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.relation.journalsince2012~-
dc.identifier.pmid27880997-
dc.relation.journalbefore~2012 Korean Journal of Hepatology (대한간학회지)-
dc.subject.keywordAdefovir-
dc.subject.keywordChronic hepatitis B-
dc.subject.keywordComplete virological response-
dc.subject.keywordSuboptimal response-
dc.subject.keywordTenofovir-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameYoon, Ki Tae-
dc.contributor.alternativeNameLee, Jung Il-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorYoon, Ki Tae-
dc.contributor.affiliatedAuthorLee, Jung Il-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.citation.volume22-
dc.citation.number4-
dc.citation.startPage443-
dc.citation.endPage449-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.22(4) : 443-449, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid41150-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.